Скачать или смотреть Optimizing CLL Care: Pharmacist-Led Strategies for Treatment Selection and Toxicity Management

Complete the activity and claim your credit today: https://bit.ly/4mN2WgR

0:00 – Introduction
2:49 - Epidemiology and burden
4:24 – Indications for treatment in CLL
5:06 – Front-line therapy
7:23 – Second-line therapy
8:29 – CLL refractory to BTKi- and BCL2i-containing regimens
11:23 – Prognostic factors: CLL-IPI, Del(11q), and MRD
12:19 – Toxicity profiles and monitoring: BTK inhibitors
14:21 - Toxicity profiles and monitoring: Venetoclax
15:08 - Toxicity profiles and monitoring: Anti-CD20 monoclonal antibodies
15:53 – Toxicity profiles and monitoring: Lisocabtagene maraleucel
16:47 – Managing toxicity: dose modification and supportive care
21:03 – Pros and cons of treatment options
24:20 – Patient education: Self-monitoring and reporting AEs
26:00 – Patient and caregiver resources
26:22 – Interprofessional collaboration
28:20 – The role of the clinical pharmacist
29:34 – Case study: Mr. GE
37:56 – Key Takeaways

Chronic lymphocytic leukemia (CLL) treatment has evolved with the introduction of targeted oral oncolytic therapies, now the standard first-line option. In this podcast, Dr. Kelsey Marciano, PharmD, BCOP, Clinical Pharmacy Specialist at UCHealth, discusses pharmacist-led strategies for treatment selection, toxicity management, patient education, and adherence to optimize CLL care.

Follow us here:
Facebook   / i3health  
Instagram   / i3health  
Linkedin   / i3health  
Soundcloud   / i3-health  
X   / i3health  

STATEMENT OF NEED
Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by an accumulation of abnormal immature or partially mature B lymphocytes in the blood and bone marrow (Wyatt et al, 2025). The introduction of targeted oral oncolytic therapies has shifted the treatment landscape for CLL, with oral agents now considered the standard first-line therapy. While these therapies provide an efficacious and convenient option for patients, they are associated with a range of toxicities that necessitate careful monitoring. Pharmacists play a crucial role in providing a comprehensive treatment approach to help navigate medication access, monitor safety and patient response, provide patient education, and optimize adherence (Wyatt et al, 2025; Upchurch & Muluneh, 2024). In this podcast, Kelsey Marciano, PharmD, BCOP, Clinical Pharmacy Specialist at UCHealth, will explore pharmacist-led strategies for treatment selection and toxicity management to optimize CLL care.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Kelsey Marciano, PharmD, BCOP, has no relevant financial relationships to disclose.

i3 Health has mitigated all relevant financial relationships.

COMMERCIAL SUPPORT
This activity is supported by a medical education grant from BeOne Medicines USA, Inc.

#CLLCare #PharmacistRole #OralOncolytics #CancerCare #OncologyEducation #PatientAdherence #ToxicityManagement #HematologicMalignancies #PrecisionOncology #patientoutcomes